PHR vs. MPLN, XNCR, MNKD, BLTE, AHCO, EYE, MIRM, MDXG, FDMT, and ALHC
Should you be buying Phreesia stock or one of its competitors? The main competitors of Phreesia include MultiPlan (MPLN), Xencor (XNCR), MannKind (MNKD), Belite Bio (BLTE), AdaptHealth (AHCO), National Vision (EYE), Mirum Pharmaceuticals (MIRM), MiMedx Group (MDXG), 4D Molecular Therapeutics (FDMT), and Alignment Healthcare (ALHC). These companies are all part of the "medical" sector.
MultiPlan (NYSE:MPLN) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.
MultiPlan has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than MultiPlan, indicating that it is currently the more affordable of the two stocks.
In the previous week, MultiPlan and MultiPlan both had 1 articles in the media. MultiPlan's average media sentiment score of 1.77 beat Phreesia's score of 0.00 indicating that Phreesia is being referred to more favorably in the news media.
MultiPlan has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
Phreesia has a net margin of -38.42% compared to Phreesia's net margin of -65.83%. Phreesia's return on equity of -8.11% beat MultiPlan's return on equity.
87.2% of MultiPlan shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 8.2% of MultiPlan shares are held by company insiders. Comparatively, 5.8% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
MultiPlan currently has a consensus price target of $2.00, indicating a potential upside of 239.39%. Phreesia has a consensus price target of $31.62, indicating a potential upside of 30.05%. Given Phreesia's higher probable upside, equities analysts clearly believe MultiPlan is more favorable than Phreesia.
Phreesia received 113 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 64.74% of users gave Phreesia an outperform vote while only 41.67% of users gave MultiPlan an outperform vote.
Summary
MultiPlan and Phreesia tied by winning 8 of the 16 factors compared between the two stocks.
Get Phreesia News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phreesia Competitors List
Related Companies and Tools
